文献速递关节外科创伤骨科

翻修髋关节置换术中术中自体血回输的系统评价与荟萃分析

Intraoperative cell salvage in revision hip arthroplasty.
PubMed 文献 · Bone Joint J · 2023-10-01

该系统评价与荟萃分析纳入11项研究(9项进入荟萃分析),评估翻修髋关节置换术中使用术中自体血回输对异体输血需求的影响。结果显示,使用自体血回输组需要异体输血的比例为44.0%(247/561),低于未使用组的65.0%(418/643),OR为0.331(95%CI 0.165至0.663,p<0.001);平均异体输血量分别为每例1.95单位(390ml)和3.25单位(650ml),平均差值为-1.91单位(95%CI -4.0至0.2,p=0.003)。作者结论支持在此类患者中常规使用自体血回输,并指出需进一步研究不同复杂度的翻修术式是否影响该效果。

要点

  • 翻修髋关节置换术使用术中自体血回输与异体输血比例降低相关(OR 0.331,95%CI 0.165至0.663,p<0.001)。
  • 使用自体血回输组异体输血比例为44.0%(247/561),未使用组为65.0%(418/643)。
  • 使用组平均异体输血量为每例1.95单位(390ml),未使用组为每例3.25单位(650ml),平均差值-1.91单位(95%CI -4.0至0.2,p=0.003)。

核心结论

  • 翻修髋关节置换术中使用术中自体血回输可显著降低异体输血需求,作者结论支持在此类患者中常规使用。
  • 作者指出需进一步研究以确定该效果是否与不同复杂度的翻修髋关节置换术式相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE(PubMed)、Embase、Scopus和Cochrane Library自建库至2022年2月24日的文献,检索策略和方案参照PRISMA声明制定。
  • 纳入标准为年龄>18岁接受翻修髋关节置换术且使用自体血回输的患者,排除使用预存自体红细胞的研究。
  • 共识别283项研究,11项纳入系统评价,9项纳入荟萃分析;荟萃分析采用随机效应模型,显著性水平设定为p=0.05。

主要发现

  • 使用自体血回输组需要异体输血的患者比例为44.0%(247/561),未使用组为65.0%(418/643),组间差异显著(p<0.001),OR为0.331(95%CI 0.165至0.663)。
  • 使用自体血回输组每例患者平均异体输血量为1.95单位(390ml)(范围0.7至4.5单位),未使用组为3.25单位(650ml)(范围1.2至7.0单位)。
  • 荟萃分析中平均差值为-1.91单位(95%CI -4.0至0.2),差异显著(p=0.003)。

临床怎么用

  • 作者结论支持在翻修髋关节置换术患者中常规使用术中自体血回输。

局限性

  • 作者指出需进一步研究以确定该效果是否与不同复杂度的翻修髋关节置换术式相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to perform a systematic review of the evidence for the use of intraoperative cell salvage in patients undergoing revision hip arthroplasty, and specifically to analyze the available data in order to quantify any associated reduction in the use of allogenic blood transfusion, and the volume which is used. METHODS: An electronic search of MEDLINE (PubMed), Embase, Scopus, and the Cochrane Library was completed from the date of their inception to 24 February 2022, using a search strategy and protocol created in conjunction with the PRISMA statement. Inclusion criteria were patients aged > 18 years who underwent revision hip arthroplasty when cell salvage was used. Studies in which pre-donated red blood cells were used were excluded. A meta-analysis was also performed using a random effects model with significance set at p = 0.05. RESULTS: Of the 283 studies which were identified, 11 were included in the systematic review, and nine in the meta-analysis. There was a significant difference (p < 0.001) in the proportion of patients requiring allogenic transfusion between groups, with an odds ratio of 0.331 (95% confidence interval (CI) 0.165 to 0.663) associated with the use of cell salvage. For a total of 561 patients undergoing revision hip arthroplasty who were treated with cell salvage, 247 (44.0%) required allogenic transfusion compared with 418 of 643 patients (65.0%) who were treated without cell salvage. For those treated with cell salvage, the mean volume of allogenic blood which was required was 1.95 units (390 ml) per patient (0.7 to 4.5 units), compared with 3.25 units (650 ml) per patient (1.2 to 7.0 units) in those treated without cell salvage. The mean difference of -1.91 units (95% CI -4.0 to 0.2) in the meta-analysis was also significant (p = 0.003). CONCLUSION: We found a a significant reduction in the need for allogenic blood transfusion when cell salvage was used in patients undergoing revision hip arthroplasty, supporting its routine use in these patients. Further research is required to determine whether this effect is associated with types of revision arthroplasty of differing complexity.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Walton TJ, Huntley D, Whitehouse SL, et al. Intraoperative cell salvage in revision hip arthroplasty. Bone Joint J. 2023. PMID: 37777212. doi:10.1302/0301-620X.105B10.BJJ-2023-0300.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。